EADV 2022: Long-Term Deucravacitinib Effective in Adults With Plaque Psoriasis
Continuous treatment with deucravacitinib for 112 weeks showed ongoing clinical efficacy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.